|
注册号: Registration number: |
ChiCTR1900025521 |
|
最近更新日期: Date of Last Refreshed on: |
2019-08-31 20:20:43 |
|
注册时间: Date of Registration: |
2019-08-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
罗涵月医师:该研究尚未获得伦理委员会批准。请于批准后再开始纳入参试者,并与我们联系上传批件。 大学生抑郁症的自动化情绪调节的干预研究以及人际信任的中介作用的验证研究 |
|
Public title: |
Research for the intervention of Automated Emotional Regulation in Depression of College Students and the Mediating Role of Interpersonal Trust |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
大学生抑郁症的自动化情绪调节的干预研究以及人际信任的中介作用的验证研究 |
|
Scientific title: |
Research for the intervention of Automated Emotional Regulation in Depression of College Students and the Mediating Role of Interpersonal Trust |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
罗涵月 |
研究负责人: |
孙琳 |
|
Applicant: |
Hanyue Luo |
Study leader: |
Lin Sun |
|
申请注册联系人电话: Applicant telephone: |
+86 15762608060 |
研究负责人电话:
Study leader's |
+86 18369695811 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2606889975@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
linsun2013@wfmc.edu.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省潍坊市潍城区宝通西街7166号 |
研究负责人通讯地址: |
山东省潍坊市潍城区宝通西街7166号 |
|
Applicant address: |
7166 Baotong Street West, Weicheng District, Weifang, Shandong |
Study leader's address: |
7166 Baotong Street West, Weicheng District, Weifang, Shandong |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
潍坊医学院 |
||
|
Applicant's institution: |
Weifang Medical University |
||
|
研究负责人所在单位: |
潍坊医学院 |
||
|
Affiliation of the Leader: |
Weifang Medical University |
||
|
是否获伦理委员会批准: |
否 |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
潍坊医学院 |
||||||||||||||||||||||
|
Primary sponsor: |
Weifang Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省潍坊市潍城区宝通西街7166号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
7166 Baotong Street West, Weicheng District, Weifang, Shandong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
实验室提供经费支持 |
||||||||||||||||||||||
|
Source(s) of funding: |
Laboratory funding support |
||||||||||||||||||||||
|
研究疾病: |
抑郁症 |
||||||||||||||||||||||
|
Target disease: |
Major Depressive Disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
利用情绪启动模型构建唤醒患者个体的自动化情绪调节的干预方案,探究自动化情绪调节是否具有对抑郁障碍的治疗作用,以及验证人际信任在干预治疗过程中的中介作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
Using the emotional priming model, we constructed an intervention program to arouse the individual's automatic emotional regulation, to explore whether the automatic emotional regulation has therapeutic effect on depression, and to verify the mediating role of interpersonal trust in the process of intervention treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
① 合并其他重症疾病; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combined with other severe diseases; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-08-31 00:00:00至 To 2019-09-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-09-20 00:00:00 至 To 2020-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
对符合所有纳入标准并同意参与本研究的40名患者随机分组,并设计两组均招募20名患者。由试验助手在EXCEL表格中根据入组时间顺序编号1-40,然后用randbetween函数赋予每一个编号一个范围介于1-100的随机数字,对生成的40个随机数字按照大小排序,排序前20位对应入组顺序的患者纳入干预组,排序后20位对应入组顺序的患者纳入对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Forty patients who met all inclusion criteria and agreed to participate in the study were randomly divided into two groups, and 20 patients were recruited in both groups. Experimentation assistant numbered 1-40 according to the time sequence of group entry in EXCEL table. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲法 请说明施盲对象。 |
|
Blinding: |
Single blind method. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2020年12月31日,可以储存于光盘,需要时提供。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
December 31, 2020. Can be stored on disc and supplied when needed. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质病历记录表和电子数据采集。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form and Electronic Data Capture. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |